Joseph Truitt
Chairman presso LARIMAR THERAPEUTICS, INC.
Patrimonio netto: 20 873 $ in data 31/03/2024
Posizioni attive di Joseph Truitt
Società | Posizione | Inizio | Fine |
---|---|---|---|
LARIMAR THERAPEUTICS, INC. | Chairman | 28/05/2020 | - |
Independent Dir/Board Member | 28/05/2020 | - | |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Director/Board Member | - | - |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Storia della carriera di Joseph Truitt
Precedenti posizioni note di Joseph Truitt
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOSPECIFICS TECHNOLOGIES CORP. | Director/Board Member | 06/04/2020 | 02/12/2020 |
Chief Executive Officer | 06/04/2020 | 02/12/2020 | |
ACHILLION PHARMACEUTICALS, INC. | Director/Board Member | 02/05/2018 | 28/01/2020 |
Chief Executive Officer | 02/05/2018 | 28/01/2020 | |
Chief Operating Officer | 11/09/2017 | 10/09/2018 | |
Corporate Officer/Principal | 05/01/2009 | 11/09/2017 | |
President | 22/02/2018 | 28/01/2020 | |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | Corporate Officer/Principal | 01/10/2007 | 01/12/2008 |
Sales & Marketing | 01/07/2006 | 01/09/2007 | |
JOHNSON & JOHNSON | Chief Operating Officer | 01/07/2006 | 01/07/2006 |
Sales & Marketing | 01/07/2006 | 01/07/2006 | |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Chief Operating Officer | 01/01/2002 | 01/01/2002 |
Sales & Marketing | 01/01/2002 | 01/01/2002 |
Formazione di Joseph Truitt
LaSalle University | Undergraduate Degree |
St. Joseph's University | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Posizioni
Director/Board Member | 4 |
Sales & Marketing | 3 |
Chief Executive Officer | 3 |
Settori
Health Technology | 9 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
LARIMAR THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY. | Health Technology |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Health Technology |
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Health Technology |
- Borsa valori
- Insiders
- Joseph Truitt
- Esperienza